CD274 and breast cancer: In 2019, US FDA approved atezolizumab in combination with nab‐paclitaxel for the first‐line treatment of unresectable locally advanced or metastatic PD‐L1 positive TNBC, making it the first immunotherapy regimen for breast cancer.